طبيب Elwira Szychot
نظرة عامة
Dr Elwira Szychot joined Great Ormond Street Hospital (GOSH) in 2021 having previously worked at the Royal Marsden Hospital in London. In 2014 she was awarded NIHR Academic Clinical Lecturership and trained dividing her time between Great Ormond Street Hospital, University College London Hospital, and the Institute of Cancer Research. She completed her core paediatric training in Oxford Deanery and academic subspecialty training in paediatric oncology in London in 2018.
Dr Szychot was awarded a PhD degree in molecular biology and MSc in paediatric oncology from University of London.
Dr Szychot specialises in paediatric neuro-oncology (tumours of the brain and spine). Her research interest focuses on the development of new drug delivery methods, such as convection- enhanced drug delivery (CED), for treatment of aggressive brain tumours.
She is a member of Children’s Brain Tumour Drug Delivery Consortium, SIOP Europe HGG/DIPG Working Group, and several national and international committees.
اللغات
- English
- Polish
المؤهلات
- Neuro-oncology (tumours of the brain and spine)
- Accelerating progress in drug delivery
EDUCATION
2012-2017 The Institute of Cancer Research, University of London, UK
2007- 2013 Oxford School of Paediatrics, Oxford, UK
1995-2001 Pomeranian Medical University, Szczecin, Poland
QUALIFICATIONS
2018 CCT in Paediatric Oncology, London Deanery
2017 MSc in Paediatric Oncology, University of London
2011 Membership of the Royal College of Paediatrics and Child Health
2005 PhD in Molecular Biology, Pomeranian Medical University, Poland
2001 MD, Pomeranian Medical University, Poland
CNS-focused drug delivery methods, such as a convection-enhanced drug delivery (CED)
The role of functional imaging in paediatric neuro-oncology
الأخبار والمنشورات
Clinical experience of Convection Enhanced Delivery (CED) of Carboplatin and Sodium valproate into the pons for the treatment of DIPG in children and young adults after radiotherapy. Szychot E, Walker D, Collins P, et al. Int J Clin Oncol. 2021 Apr;26(4):647-658.
Predicting Outcome in Childhood Diffuse Midline Gliomas Using Magnetic Resonance Imaging Based Texture Analysis. Szychot E, Youssef A, Ganeshan B, Endozo R, Hyare H, Gains J, Mankad K, Shankar A. J Neuroradiol 2020 Mar 14.
Children's Cancer and Leukaemia Group (CCLG): review and guidelines for the management of meningioma in children, teenagers and young adults. Szychot E, Goodden J, Whitfield G, Curry S. Br J Neurosurg 2020 Mar 2:1-12.
Estimating brain volume loss after radiation therapy in children treated for posterior fossa tumors (Corpus callosum and whole brain volume changes following radiotherapy in children). Szychot E, Seunarine KK, Robles CA, Mandeville H, Mankad K, Clark C, Peregud-Pogorzelski J, deSouza N. Adv Clin Exp Med. 2020;29(3): 1-7 (online)
Impact of induction chemotherapy, hyperfractionated accelerated radiotherapy (HART) and high-dose thiotepa on brain volume loss and functional status of children with primitive neuroectodermal tumour (PNET). Szychot E, Seunarine K, Mankad K, Thust S, Clark C, Gaze M, Michalski A. Pediatr Blood Cancer. 2017 Nov;64(11).
Variant histology nodular lymphocyte predominant Hodgkin lymphoma- a route to transformation?" Szychot E, Shankar A, et al. Br J Haematol. 2018 May;181(3):403-406.
The evidence for efficacy of the immunotherapy in children with high-risk neuroblastoma. Szychot E, et al. Adv Hyg Exp Med 2016 Sep 28;70(0):1001-1004.
How have advances in our understanding of the molecular genetics of paediatric leukaemia led to improved targeted therapies for these diseases? – short review. Szychot E, et al. Adv Clin Exp Med 2014:; 23(3):469-474.
Wilms’ tumor: biology, diagnosis and treatment. Szychot E, Apps J, Pritchard- Jones K. Transl Pediatr 2014; 3(1): 12-24.
Will therapies that target tumour suppressor genes be useful in cancer treatment? Szychot E, et al. Adv Clin Exp Med 2013; 22(6): 861-4.
أحل طفلك إلى طبيب Elwira Szychot
استخدم النموذج التالي لإحالة طفل للعلاج. سيتصل بك أحد أعضاء فريقنا خلال يومي عمل (الإثنين – الجمعة)
الإجابة ضرورية للاستمرار
